{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:18:08Z","timestamp":1780413488287,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.amepre.2023.09.016","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:55:19Z","timestamp":1695243319000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["State Laws That Require Coprescribing Opioids and Naloxone and Codispensing Practices"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4790-4731","authenticated-orcid":false,"given":"Kayla N.","family":"Tormohlen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma E.","family":"McGinty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2023.09.016_bib0001","unstructured":"National Center for Health Statistics. U.S. overdose deaths in 2021 increased half as much as in 2020 - but are still up 15%. http:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm. Published 2022. Accessed January 4, 2023."},{"key":"10.1016\/j.amepre.2023.09.016_bib0002","unstructured":"Centers for Disease Control and Prevention injury center. Death rate maps & graphs. Drug overdose. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html. Published 2022. Accessed January 18, 2023."},{"key":"10.1016\/j.amepre.2023.09.016_bib0003","unstructured":"National Institute on Drug Abuse. Drug overdose death rates. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates. Published 2023. Accessed March 2, 2023."},{"issue":"2","key":"10.1016\/j.amepre.2023.09.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0919","article-title":"Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries","volume":"1","author":"Hernandez","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amepre.2023.09.016_bib0005","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality","volume":"17","author":"Dasgupta","year":"2016","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.amepre.2023.09.016_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.15163","article-title":"Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States","volume":"116","author":"Smart","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.amepre.2023.09.016_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/20503245221112575","article-title":"State naloxone co-prescribing laws show mixed effects on overdose mortality rates","volume":"8","author":"Duska","year":"2022","journal-title":"Drug Sci Policy Law"},{"issue":"4","key":"10.1016\/j.amepre.2023.09.016_bib0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amepre.2022.10.009","article-title":"The impact of naloxone coprescribing mandates on opioid-involved overdose deaths","volume":"64","author":"Sohn","year":"2023","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.amepre.2023.09.016_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.amepre.2023.09.016_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.amepre.2023.09.016_bib0011","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2105\/AJPH.2020.305620","article-title":"Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014\u20132018","volume":"110","author":"Green","year":"2020","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.amepre.2023.09.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6215","article-title":"Association of naloxone coprescription laws with naloxone prescription dispensing in the United States","volume":"2","author":"Sohn","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2023.09.016_bib0013","unstructured":"IBM Watson Health. Watson health. IBM MarketScan Research Databases for Life Science Researchers. https:\/\/www.ibm.com\/downloads\/cas\/0NKLE57Y."},{"key":"10.1016\/j.amepre.2023.09.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107896","article-title":"Legal requirements and recommendations to prescribe naloxone","volume":"209","author":"Haffajee","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amepre.2023.09.016_bib0015","unstructured":"The Network for Public Health Law. Fact sheet - naloxone prescription mandates. https:\/\/www.networkforphl.org\/resources\/naloxone-prescription-mandates\/. Accessed September 14, 2023."},{"issue":"5","key":"10.1016\/j.amepre.2023.09.016_bib0016","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.2019.7988","article-title":"Naloxone co-prescribing to patients receiving prescription opioids in the Medicare Part D Program, United States, 2016\u20132017","volume":"322","author":"Jones","year":"2019","journal-title":"JAMA"},{"issue":"536","key":"10.1016\/j.amepre.2023.09.016_bib0017","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/01621459.2021.1929245","article-title":"The augmented synthetic control method","volume":"116","author":"Ben-Michael","year":"2021","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.amepre.2023.09.016_bib0018","series-title":"Balancing, regression, difference-in-differences and synthetic control methods: a synthesis","author":"Doudchenko","year":"2016"},{"key":"10.1016\/j.amepre.2023.09.016_bib0019","first-page":"1","article-title":"A design-based perspective on synthetic control methods","author":"Bottmer","year":"2023","journal-title":"J Bus Econ Stat"},{"issue":"12","key":"10.1016\/j.amepre.2023.09.016_bib0020","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1257\/aer.20190159","article-title":"Synthetic difference-in-differences","volume":"111","author":"Arkhangelsky","year":"2021","journal-title":"Am Econ Rev"},{"issue":"5","key":"10.1016\/j.amepre.2023.09.016_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3209","article-title":"Naloxone prescriptions among commercially insured individuals at high risk of opioid overdose","volume":"2","author":"Follman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2023.09.016_bib0022","first-page":"13","article-title":"Considering the potential benefits of over-the-counter naloxone","volume":"10","author":"Evoy","year":"2021","journal-title":"Integr Pharm Res Pract"},{"key":"10.1016\/j.amepre.2023.09.016_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108569","article-title":"Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017\u201318","volume":"221","author":"Stein","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"10.1016\/j.amepre.2023.09.016_bib0024","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s11606-015-3394-3","article-title":"Overdose education and naloxone for patients prescribed opioids in primary care: A qualitative study of primary care staff","volume":"30","author":"Binswanger","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.amepre.2023.09.016_bib0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/08897077.2016.1238431","article-title":"Co-prescribing naloxone does not increase liability risk","volume":"37","author":"Davis","year":"2016","journal-title":"Subst Abus"},{"key":"10.1016\/j.amepre.2023.09.016_bib0026","unstructured":"Leg.state.fl.us. Florida statutes section 456.072.http:\/\/www.leg.state.fl.us\/Statutes\/index.cfm?App_mode=Display_Statute&URL=0400-0499\/0456\/Sections\/0456.072.html#:\u223c:text=(m)%20Making%20deceptive%2C%20untrue,licensee%20or%20a%20third%20party. Accessed September 29, 2023."},{"key":"10.1016\/j.amepre.2023.09.016_bib0027","unstructured":"R.I. Gen. Laws A. \u00a7 21-28-4.09.https:\/\/casetext.com\/statute\/general-laws-of-rhode-island\/title-21-food-and-drugs\/chapter-21-28-uniform-controlled-substances-act\/article-21-28-401-offenses-and-penalties\/section-21-28-409-general-penalty-clause. Accessed September 29, 2023."},{"issue":"5","key":"10.1016\/j.amepre.2023.09.016_bib0028","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.japh.2022.03.015","article-title":"Pharmacy naloxone codispensing: a mixed methods study of practices and perspectives under a statewide standing order program","volume":"62","author":"Pollini","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.amepre.2023.09.016_bib0029","first-page":"101","article-title":"Community-based opioid overdose prevention programs providing naloxone \u2014 United States, 2010","volume":"61","author":"Wheeler","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"10.1016\/j.amepre.2023.09.016_bib0030","first-page":"631","article-title":"Opioid overdose prevention programs providing naloxone to laypersons \u2014 United States, 2014","volume":"64","author":"Wheeler","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2023.09.016_bib0031","unstructured":"Hoffman J. Over-the-counter Narcan could save more lives. But price and stigma are obstacles. The New York Times. https:\/\/www.nytimes.com\/2023\/03\/28\/health\/narcan-otc-price.html. Published 2023. Accessed September 14, 2023."},{"issue":"5","key":"10.1016\/j.amepre.2023.09.016_bib0032","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/1475-6773.13666","article-title":"Confounding and regression adjustment in difference-in-differences studies","volume":"56","author":"Zeldow","year":"2021","journal-title":"Health Serv Res"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074937972300377X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074937972300377X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:10:38Z","timestamp":1760083838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074937972300377X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S074937972300377X"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2023.09.016","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State Laws That Require Coprescribing Opioids and Naloxone and Codispensing Practices","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2023.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}